The Japanese Study for Efficacy of Luseogliflozin on composite Endpoint, Compared to DPP-4 inhibitors, in Type 2 diabetes mellitus patients (J-SELECT study)
Latest Information Update: 10 Jul 2023
At a glance
- Drugs Luseogliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms J-SELECT study
- 06 Jul 2023 Results assessing Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors in patients with type 2 diabetes mellitus published in the Diabetes Therapy
- 31 May 2022 Planned End Date changed from 30 Apr 2021 to 31 Dec 2021.
- 30 Nov 2021 Status changed from recruiting to active, no longer recruiting.